| Catalog Number | KRP076 | 
																		| Alias | Kininogen-1, Kininogen-1 , Alpha-2-thiol proteinase inhibitor, Fitzgerald factor, High molecular weight kininogen, HMWK, Williams-Fitzgerald-Flaujeac factor, [Cleaved into: Kininogen-1 heavy chain; T-kinin , Ile-Ser-Bradykinin, ; Bradykinin , Kallidin I,  | 
																		| Size | 20ug, 50ug, 100ug, 200ug, 1mg | 
																		| Product Description | Human KNG1(19-644 aa) | 
																		| Molecular Name | KNG1 | 
																		| Product Introduction | Kininogen-1干扰病毒感染的免疫因子,调节免疫应答。。 | 
																		| Molecular Weight | 120 kDa | 
																		| Expression System | HEK293F Cells | 
																		| Species | Human | 
																		| Concentration | 联系销售经理获得最新批次的浓度 | 
																		| Purity | ≥95% | 
																		| SDS-PAGE |   | 
																		| Purification | Affinity Purification | 
																		| Uniprot ID | P01042-1 | 
																		| Storage Condition | Store the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -20℃. Avoid repeated freeze-thaw cycles. | 
																		| Formulation | Supplied in PBS | 
																		| Shipping Condition | This product is shipped on ice packs or dry ice. | 
																		| Background | Kininogens are inhibitors of thiol proteases. HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. LMW-kininogen inhibits the aggregation of thrombocytes. LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.; [Bradykinin]: The active peptide bradykinin is a potent vasodilatator that is released from HMW-kininogen shows a variety of physiological effects: (A) influence in smooth muscle contraction, (B) induction of hypotension, (C) natriuresis and diuresis, (D) decrease in blood glucose level, (E) it is a mediator of inflammation and causes (E1) increase in vascular permeability, (E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action). {ECO:0000305|PubMed:4322742, ECO:0000305|PubMed:6055465}. | 
																		| Endotoxin | < 0.1 EU per ug | 
																		| Biological Activity | Measured by its ability to inhibit papain cleavage of a fluorogenic peptide substrate Z-FR- AMC. The IC50 value is < 3 nM, as measured under the described conditions. | 
																		| Product Declaration | 该产品仅供科研使用,不可直接用于人体或注射。 |